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the COVID-19 pandemic — a pulmonologist’s perspective
To the Editor
The novel coronavirus disease 2019 
(COVID-19) caused by the SARS-CoV-2 virus 
continues to wreak havoc all over the world 
with approximately 57,714,184 infections and 
1,373,065 deaths reported to date [1]. No definite 
therapy is available yet and vaccines are still 
under development. As the entire health-care 
system is entangled in tackling the pandemic, 
interim guidelines were formulated in order to 
organize optimal prioritization of health resourc-
es to avoid the compromise of non-COVID care. 
However, these guidelines were directed at gener-
alized management of all non-COVID-19 related 
illness. Our letter focuses on the management 
of the common non-COVID respiratory illness-
es, thereby aiming to provide clarity to treating 
physicians. Further, chronic lung disease is an 
independent risk factor for severe COVID-19 and 
mortality [2].
Bronchial asthma, defined by a history of 
variable respiratory symptoms (wheezing, short-
ness of breath, chest tightness, and cough) and 
variable expiratory airflow limitation, affects 
nearly 300 million people worldwide and leads 
to increased mortality in middle and low-in-
come countries. The Global Initiative for Asthma 
(GINA) recommends continuation of asthma 
medications (particularly inhaled corticosteroids, 
oral corticosteroids, and biological therapy) as 
sudden discontinuation may lead to poor asthma 
control. Apart from pharmacotherapy, a written 
asthma plan aimed at recognizing exacerbations is 
advised. The main change in asthma care includes 
the avoidance of nebulizers and the preferential 
use of pressurised metered-dose inhalers (pMDI) 
with a spacer to avoid aerosol generation. The 
use of spirometry and peak-flow meters should 
be avoided unless compelling indications influ-
encing clinical management arises. In the case 
of aerosol-generating procedures, strict infection 
control measures need to be adopted and personal 
protective equipment (PPE) should be used [3]. 
Until further evidence is available, it is safe to 
incorporate these measures into asthma manage-
ment during the COVID-19 pandemic. Chronic 
obstructive pulmonary disease (COPD) is the 
third leading cause of death in the world and is 
a significant risk factor for poor patient outcome 
(ICU admission, invasive ventilation, or death) in 
COVID-19 [4]. The global initiative for obstructive 
lung disease (GOLD) interim guidelines advise 
for the continuation of maintenance therapy and 
adherence to the advice of local health teams in 
order to minimise the chance of disease spread 
[5]. Pulmonary rehabilitation (PR) is a key com-
ponent of stable COPD management and can be 
performed via programs conducted online or by 
telephone [6]. In suspected COPD exacerbations, 
it is advised to rule out COVID-19 while effective-
ly managing the exacerbation.
Pulmonary tuberculosis (PTB) continues 
to be one the leading cause of morbidity and 
mortality, especially in high-TB burden coun-
tries. Data regarding COVID-19 infection in PTB 
is limited and the World Health Organization 
(WHO) has issued an urgent message highlight-
ing the need to maintain continuity of essential 
services for people affected with TB during the 
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COVID-19 pandemic as it threatens to reverse the 
gains made in TB prevention and care. Patients 
with PTB and COVID-19 are expected to have 
poorer outcomes if anti-tuberculous therapy is 
interrupted. Early diagnosis, appropriate treat-
ment, and preventive measures such as cough 
etiquette, personal hygiene, and social distancing 
need to be adopted as they help in reducing the 
transmission of TB and COVID-19. TB patients 
should be in constant communication with health 
care facilities to aid in the management of adverse 
drug reactions, comorbidities, nutritional and 
mental health support, and restocking of medical 
supplies. Steps have to be taken to ensure the 
timely availability of TB medicines and collection 
of sputum samples for follow-up testing. Until the 
pandemic subsides, a decentralized home-based 
treatment approach should be initiated for all 
TB patients. However, it is important to note that 
this may lead to an increased risk of household 
transmission of TB [7].
Lung cancer is the most common malignancy 
worldwide resulting in 2.09 million deaths in 
2018. Lung cancer patients also have an increased 
probability of contracting SARS-CoV-2 infection 
due to immunosuppression from the malignan-
cy, chemoradiation, advanced age, chronic lung 
disease, and other comorbidities. Diagnostic 
delay may occur in COVID-19 suspected/posi-
tive patients as elective/emergent bronchoscopy 
is postponed until 28-30 days after resolution 
of symptoms and viral shedding. Enrolment of 
new patients for chemotherapy has also been 
put on hold temporarily at various cancer cen-
tres. Diagnosis of lung cancer should be aimed at 
obtaining tissue with the least invasive method 
and to perform urgent bronchoscopies in a safe 
and timely manner after taking into consideration 
local availability of resources [8]. Apart from 
diagnosis and medical management, surgery in 
resectable lung cancer is also affected as elective 
surgeries are currently rescheduled. Enrolment 
in chemotherapy and radiotherapy should be 
initiated in a systemic manner after effectively 
ruling out SARS-CoV-2 infection. The decision 
for timing of surgery should be individualized on 
a case by case basis. In case of urgent surgeries, 
they should be preferentially done in negative 
pressure isolation rooms with full PPE [9].
Community acquired pneumonia (CAP) can 
be due to bacterial or viral pathogens. The most 
common organisms include streptococci, mo-
raxella catarrhalis, haemophilus influenza B, 
chlamydia, and staph aureus. Viruses contribute 
to one-third of CAP. According to Medley et al. 
[10], empirical antibiotics are recommended 
against the most common CAP pathogens but are 
not routinely indicated in COVID-19 pneumonia. 
Cultures are not routinely advised and should be 
obtained only when multidrug resistant organ-
isms are suspected. Measuring serum procalci-
tonin can help to prevent antibiotic overuse. Use 
of steroids or any immunomodulating agents are 
not indicated in bacterial CAP.
Apart from the above respiratory diseases, 
there are several other chronic lung diseases for 
which no definitive guidance is available yet and 
are beyond the scope of this article. The optimal 
management of these major non-COVID respirato-
ry illnesses is paramount in reducing the burden 
of overwhelmed health care systems tackling the 
COVID-19 pandemic. Timely testing, ensuring 
adherence and compliance to therapy through 
social networking systems, telemedicine consul-
tations, access to medication and hospital care in 
case of worsening symptoms, PR, and counselling 
counseling, and education social stigmas are the 
way forward in the new normal of learning to live 
with COVID-19 and will help recover lost ground 
on non-COVID respiratory care. As the saying 
goes, “the battle may have been lost, but the war 
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